Roche presented phase 3 data showing its BTK inhibitor fenebrutinib reduced the risk of disability progression by 12% versus Ocrevus in primary progressive multiple sclerosis (PPMS), meeting non‑inferiority criteria in a late‑stage trial disclosed at ACTRIMS. The company released detailed numbers linking the BTK inhibitor to clinical benefit in the PPMS population. Roche positioned the win as validation for BTK inhibition in progressive MS, providing clinicians and investors with comparative metrics against an established B cell therapy. The published data offer granular endpoints and may influence competitive positioning and regulatory discussions for next‑generation MS treatments.